Durvalumab with or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
- Naiyer A. Rizvi
- , Byoung Chul Cho
- , Niels Reinmuth
- , Ki Hyeong Lee
- , Alexander Luft
- , Myung Ju Ahn
- , Michel M. Van Den Heuvel
- , Manuel Cobo
- , David Vicente
- , Alexey Smolin
- , Vladimir Moiseyenko
- , Scott J. Antonia
- , Sylvestre Le Moulec
- , Gilles Robinet
- , Ronald Natale
- , Jeffrey Schneider
- , Frances A. Shepherd
- , Sarayut Lucien Geater
- , Edward B. Garon
- , Edward S. Kim
- Columbia University
- Yonsei University
- Asklepios Lung Clinic
- Chungbuk National University
- Leningrad Regional Clinical Hospital
- Netherlands Cancer Institute
- Hospital Regional Universitario Carlos Haya
- Hospital Universitario Virgen Macarena
- Ministry of Defence of the Russian Federation
- Oncological Clinical Research Center
- Moffitt Cancer Center
- Centre Georges-François Leclerc
- Université de Bretagne Occidentale
- Cedars-Sinai Medical Center
- NYU Winthrop Hospital
- University of Toronto
- Prince of Songkla University
- University of California at Los Angeles
- Levine Cancer Institute
- Yale University
- Kindai University
- AstraZeneca
- University of Lausanne
Research output: Contribution to journal › Article › peer-review
573
Link opens in a new tab
Scopus
citations